Año: 2012
Journal Impact Factor (JIF): 4.0680
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| MICROBIOLOGY | SCIE | 27/116 | Q1 | T1 | D3 |
Año: 2017
Journal Citation Indicator (JCI): 1,190
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| MICROBIOLOGY | 28/145 | Q1 | T1 | D2 | 81,03 |
Año:
2012
CiteScore:
7,100
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Microbiology (medical) | 11/96 | Q1 | T1 | D2 |
SJR año:
2012
Factor de Impacto:
2,148
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Microbiology (medical) | 8/119 | Q1 | T1 | D1 |
| Agencia | Código de Proyecto |
|---|---|
| Achaogen | - |
| Aires | - |
| ALBAN | - |
| American Proficiency Institute (API) | - |
| Anacor | - |
| Astellas | - |
| Astellas Pharma | - |
| AstraZeneca | - |
| Bayer | - |
| bioMerieux | - |
| Cempra | - |
| Cerexa | - |
| Contrafect | - |
| Cosmo Technologies | - |
| Cubist | - |
| Daiichi | - |
| Dipexium | - |
| Enanta | - |
| European Union | - |
| Ferrer International | - |
| Furiex | - |
| Gilead Sciences | - |
| GlaxoSmithKline | - |
| Innovative Biosensors | - |
| Instituto de Salud Carlos III | - |
| Johnson Johnson (JJ) | - |
| LegoChem Biosciences Inc. | - |
| Medicines Co. | - |
| Meiji Seika Kaisha | - |
| Merck | - |
| Merck Sharp and Dohme | - |
| Merck, Astellas | - |
| Mutua Madrile a Foundation | - |
| Nabriva | - |
| Novartis | - |
| Paratek | - |
| Pfizer | - |
| Pfizer (Wyeth) | - |
| PPD Therapeutics | - |
| Premier Research Group | - |
| PurThread Technologies | - |
| Ramon Areces Foundation | - |
| Rempex | - |
| Rib-X Pharmaceuticals | - |
| Schering Plough | - |
| Seachaid | - |
| Shionogi | - |
| Shionogi USA | - |
| Soria Melguizo SA | - |
| Spanish Agency for International Cooperation | - |
| Spanish Health Research Fund | - |
| Spanish Ministry of Culture and Education | - |
| Theravance | - |
| ThermoFisher | - |
| TREK Diagnostics | - |
| Vertex Pharmaceuticals | - |
| # | Autor | Afiliación |
|---|---|---|
| 1 | JMI Laboratories Incorporated (United States) | |
| 2 | Espinel-Ingroff, A. | Virginia Commonwealth University Medical Center (United States) |
| 3 | Canton, E. | Hospital Universitari i Politècnic La Fe (Spain) |
| 4 | Castanheira, M. | JMI Laboratories Incorporated (United States) |
| 5 | Cuenca-Estrella, M. | Centro Nacional de Microbiologia (Spain) |
| 6 | Diekema, D. J. | University of Iowa (United States) |
| 7 | Fothergill, A. | University of Texas Health Science Center at San Antonio (United States) |
| 8 | Fuller, J. | University of Alberta (Canada) |
| 9 | Ghannoum, M. | University Hospitals Case Medical Center (United States) |
| 10 | Jones, R. N. | JMI Laboratories Incorporated (United States) |
| 11 | Lockhart, S. R. | Centers for Disease Control and Prevention (United States) |
| 12 | Martin-Mazuelos, E. | Hospital Universitario de Valme (Spain) |
| 13 | Melhem, M. S.C. | Adolfo Lutz Institute Public Health Reference Center (Brazil) |
| 14 | Ostrosky-Zeichner, L. | University of Texas Health Science Center at Houston (United States) |
| 15 | Pappas, P. | The University of Alabama at Birmingham (United States) |
| 16 | Pelaez, T. | Hospital General Universitario Gregorio Marañon (Spain) |
| 17 | Peman, J. | Hospital Universitari i Politècnic La Fe (Spain) |
| 18 | Rex, J. | AstraZeneca (United Kingdom) |
| 19 | Szeszs, M. W. | Instituto Adolfo Lutz (Brazil) |
